Following the call for vaccine researchers to submit their vaccine candidate for testing in a mouse model, we are delighted to announce the selection of three candidates.
Based on predetermined criteria, the Portfolio Advisory Committee has selected candidates who are eligible to participate in the head-to-head comparison testing program within the TBVAC-HORIZON project. The assessment will evaluate the ability of vaccines to reduce bacterial load using a standard mouse model of vaccination and pulmonary challenge with Mycobacterium tuberculosis.
The following candidates have been selected:
- ID93 GLA-3M052-LS, a protein subunit vaccine with a protein that has reached clinical phases and an adjuvant designed to induce strong Th1 as well as mucosal Ab responses.
- The mc27902 candidate, an attenuated vaccine based on an auxotrophic strain of Mycobacterium tuberculosis.
- PNx6 is a self-assembling, self-adjuvanting vaccine containing 6 peptides selected based on immunological and chemical properties.
The head-to-head comparison will start in the coming months to encourage further development of the candidate with the aim of diversifying the TB vaccine development pipeline.
If you wish for your vaccine candidate to take part in the head-to-head assessment, please note that a total of four calls are scheduled within the TBVAC-HORIZON project. The next round will be announced in the first quarter of 2025!
